MCID: ACT098
MIFTS: 55

Acute Erythroid Leukemia

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Acute Erythroid Leukemia

MalaCards integrated aliases for Acute Erythroid Leukemia:

Name: Acute Erythroid Leukemia 12 20 37
Acute Erythroleukemia 20 17 70
Erythroleukemia 20 54 17
Acute Myeloid Leukemia, M6 Type 29 6
Acute Myeloid Leukemia Fab-M6 20 70
Acute Erythroleukemia - M6a Subtype 70
Acute Erythroleukemia - M6b Subtype 70
Acute Erythroleukemia M6a Subtype 20
Acute Erythroleukemia M6b Subtype 20
Acute Erythroblastic Leukemia 70
Acute Myeloid Leukemia M6 20
Di Guglielmo's Syndrome 20
Di Guglielmo Syndrome 20
Aml M6 20
Aml-M6 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0080780
NCIt 50 C8923
ICD10 32 C94.0
UMLS 70 C0023440 C2930974 C2930975 more

Summaries for Acute Erythroid Leukemia

Disease Ontology : 12 An acute myeloid leukemia that is characterized by a predominant immature erythroid population.

MalaCards based summary : Acute Erythroid Leukemia, also known as acute erythroleukemia, is related to anemia, congenital dyserythropoietic, type iii and refractory anemia. An important gene associated with Acute Erythroid Leukemia is ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs Cytarabine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include myeloid, spleen and bone marrow, and related phenotypes are anemia and pancytopenia

Wikipedia : 73 Acute erythroid leukemia is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the... more...

Related Diseases for Acute Erythroid Leukemia

Diseases related to Acute Erythroid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 anemia, congenital dyserythropoietic, type iii 32.0 KLF1 GATA1
2 refractory anemia 30.3 JAK2 EPO
3 acute megakaryocytic leukemia 30.2 JAK2 GATA1 EPOR
4 thalassemia 30.1 HBG1 HBB GATA1
5 leukemia 30.1 SPI1 JAK2 FLI1 ERBB3 EPOR
6 myelodysplastic syndrome 29.8 JAK2 GATA1 EPOR EPO
7 leukemia, chronic myeloid 29.8 JAK2 GATA1 EPOR EPO
8 polycythemia vera 29.7 NFE2 JAK2 EPOR EPO
9 fetal hemoglobin quantitative trait locus 1 29.7 HBG1 HBB
10 congenital dyserythropoietic anemia 29.7 KLF1 GATA1 EPO
11 hemolytic anemia 29.6 KLF1 HBG1 HBB EPO
12 polycythemia 29.5 NFE2 JAK2 HBB EPOR EPO
13 hemoglobin h disease 29.5 KLF1 HBG1 HBB EPO
14 hemoglobinopathy 29.5 KLF1 HBG1 HBB GATA1 EPO
15 sickle cell anemia 29.4 HBG1 HBB EPO
16 myeloproliferative neoplasm 29.3 SPI1 JAK2 GATA1 EPOR EPO
17 myelofibrosis 29.2 NFE2 JAK2 GATA1 EPOR EPO
18 hereditary spherocytosis 29.1 NFE2 KLF1 HBG1 HBB GATA1
19 essential thrombocythemia 29.0 NFE2 JAK2 GATA1 EPOR EPO
20 alpha-thalassemia 29.0 KLF1 HBG1 HBB GATA1 EPO
21 thrombocytopenia 28.9 NFE2 JAK2 GATA1 FLI1 EPOR EPO
22 deficiency anemia 28.8 NFE2 KLF1 JAK2 HBG1 HBB GATA1
23 beta-thalassemia 28.5 KLF1 JAK2 HBG1 HBB GATA1 EPOR
24 erythroleukemia, familial 11.3
25 folate malabsorption, hereditary 10.9
26 leukemia, acute myeloid 10.5
27 myeloid leukemia 10.4
28 splenomegaly 10.4
29 pertussis 10.4
30 acute leukemia 10.3
31 pernicious anemia 10.2
32 erythrocytosis, familial, 8 10.2 JAK2 EPOR
33 splenic infarction 10.2 JAK2 HBB
34 macrocytic anemia 10.2
35 myelodysplastic syndrome with excess blasts 10.2
36 retinoblastoma 10.2
37 amegakaryocytic thrombocytopenia, congenital 10.1 JAK2 GATA1
38 neutrophil-specific granule deficiency 10.1 SPI1 GATA1
39 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.1 JAK2 EPO
40 myelophthisic anemia 10.1 JAK2 EPO
41 anemia, congenital dyserythropoietic, type ib 10.1 KLF1 GATA1
42 cutaneous porphyria 10.1 KLF1 GATA1
43 inflammatory bowel disease 27 10.1 GATA1 EPO
44 anemia, congenital dyserythropoietic, type iv 10.1 KLF1 GATA1
45 lumbosacral lipoma 10.1 EPOR EPO
46 progressive myoclonus epilepsy 9 10.1 EPOR EPO
47 pancytopenia 10.1
48 anemia of prematurity 10.1 EPOR EPO
49 splenic sequestration 10.1 HBB EPO
50 teratoma 10.1

Graphical network of the top 20 diseases related to Acute Erythroid Leukemia:



Diseases related to Acute Erythroid Leukemia

Symptoms & Phenotypes for Acute Erythroid Leukemia

Human phenotypes related to Acute Erythroid Leukemia:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 anemia 31 frequent (33%) HP:0001903
2 pancytopenia 31 frequent (33%) HP:0001876
3 leukopenia 31 frequent (33%) HP:0001882
4 refractory anemia with ringed sideroblasts 31 frequent (33%) HP:0004828
5 abnormal proerythroblast morphology 31 frequent (33%) HP:0025035
6 bone marrow hypercellularity 31 frequent (33%) HP:0031020
7 erythroid hypoplasia 31 frequent (33%) HP:0012133
8 bone marrow hypocellularity 31 occasional (7.5%) HP:0005528

MGI Mouse Phenotypes related to Acute Erythroid Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.01 EPO EPOR ERBB3 FLI1 GATA1 HSF2
2 embryo MP:0005380 9.97 EPO EPOR ERBB3 FLI1 GATA1 JAK2
3 immune system MP:0005387 9.97 EPO EPOR ERBB3 FLI1 GATA1 JAK2
4 mortality/aging MP:0010768 9.85 EPO EPOR ERBB3 FLI1 GATA1 HSF2
5 liver/biliary system MP:0005370 9.8 EPO EPOR FLI1 GATA1 JAK2 KLF1
6 neoplasm MP:0002006 9.35 ERBB3 FLI1 JAK2 NFE2 SPI1
7 normal MP:0002873 9.17 EPO EPOR ERBB3 GATA1 HSF2 JAK2

Drugs & Therapeutics for Acute Erythroid Leukemia

Drugs for Acute Erythroid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
6
Daunorubicin Approved Phase 3 20830-81-3 30323
7
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
Idarubicin Approved Phase 3 58957-92-9 42890
10
Thioguanine Approved Phase 3 154-42-7 2723601
11
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
12
Busulfan Approved, Investigational Phase 3 55-98-1 2478
13
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
14
Lenograstim Approved, Investigational Phase 3 135968-09-1
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
17 Vitamin B9 Phase 3
18 Antibiotics, Antitubercular Phase 3
19 Etoposide phosphate Phase 3
20 Gastrointestinal Agents Phase 3
21 Analgesics, Non-Narcotic Phase 3
22 Folic Acid Antagonists Phase 3
23 Anti-Retroviral Agents Phase 3
24 Interleukin-2 Phase 3
25 Hormones Phase 3
26 glucocorticoids Phase 3
27
asparaginase Phase 3
28 Analgesics Phase 3
29 Antiemetics Phase 3
30 Vitamin B Complex Phase 3
31 Hormone Antagonists Phase 3
32 Hydrocortisone-17-butyrate Phase 3
33 Dermatologic Agents Phase 3
34 Antineoplastic Agents, Hormonal Phase 3
35 Hydrocortisone hemisuccinate Phase 3
36 N-Methylaspartate Phase 3
37 Folate Phase 3
38 Anti-Bacterial Agents Phase 3
39 Anti-HIV Agents Phase 3
40 BB 1101 Phase 3
41 Hydrocortisone 17-butyrate 21-propionate Phase 3
42 Anti-Inflammatory Agents Phase 3
43
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
44
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
45
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
46
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
47 Anti-Infective Agents Phase 2
48 Antirheumatic Agents Phase 2
49 Antiviral Agents Phase 2
50 Histone Deacetylase Inhibitors Phase 1, Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
2 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML) Completed NCT00305773 Phase 2 vorinostat;vorinostat
3 A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent Completed NCT02019069 Phase 2 liposomal cytarabine-daunorubicin CPX-351
4 Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies Recruiting NCT04083170 Phase 2 Fludarabine;Cyclophosphamide;Thiotepa
5 A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS) Active, not recruiting NCT00392353 Phase 1, Phase 2 Azacitidine;Vorinostat
6 Phase II Study of Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia in First Remission Withdrawn NCT00101140 Phase 2 anti-thymocyte globulin;fludarabine phosphate;thiotepa
7 Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00462761 Phase 1 AC220
8 Identification of de Novo Fanconi Anemia Patients Using FANCD2 Western Blots Completed NCT01146210
9 Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing Completed NCT02861651

Search NIH Clinical Center for Acute Erythroid Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Erythroid Leukemia cell therapies at LifeMap Discovery.

Genetic Tests for Acute Erythroid Leukemia

Genetic tests related to Acute Erythroid Leukemia:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia, M6 Type 29 ERBB3

Anatomical Context for Acute Erythroid Leukemia

MalaCards organs/tissues related to Acute Erythroid Leukemia:

40
Myeloid, Spleen, Bone Marrow, Nk Cells, Endothelial, Bone, Breast

Publications for Acute Erythroid Leukemia

Articles related to Acute Erythroid Leukemia:

(show top 50) (show all 4730)
# Title Authors PMID Year
1
A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. 6 61
27416908 2016
2
USF and NF-E2 cooperate to regulate the recruitment and activity of RNA polymerase II in the beta-globin gene locus. 61 54
20236933 2010
3
Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk. 61 54
20016000 2010
4
Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing. 54 61
19716852 2010
5
Immobilization, stabilization, and activation of human stem cell factor (SCF) on fragmin/protamine microparticle (F/P MP)-coated plates. 54 61
19637375 2010
6
PU.1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells. 61 54
19955566 2010
7
Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. 54 61
19965627 2010
8
Regulated expression of the alpha isoform of the human thromboxane A2 receptor during megakaryocyte differentiation: a coordinated role for WT1, Egr1, and Sp1. 54 61
19747485 2009
9
Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. 54 61
19682090 2009
10
Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation. 54 61
19581930 2009
11
Enrichment of Sca1+ hematopoietic progenitors in polycythemic mice inhibits leukemogenesis. 54 61
19584401 2009
12
Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia. 61 54
19282832 2009
13
Regulation of hematopoietic cell development and function by Stat3. 54 61
19482615 2009
14
Human stem cell factor (SCF) is a heparin-binding cytokine. 54 61
19074504 2009
15
The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. 61 54
19212691 2009
16
Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. 61 54
18694847 2009
17
Transcriptional regulation of the human prostacyclin receptor gene is dependent on Sp1, PU.1 and Oct-1 in megakaryocytes and endothelial cells. 61 54
19118563 2009
18
Regulation of transferrin receptor 2 in human cancer cell lines. 61 54
19019709 2009
19
Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. 54 61
19713696 2009
20
Phorbol 12-myristate 13-acetate (PMA) responsive sequence in Galphaq promoter during megakaryocytic differentiation. Regulation by EGR-1 and MAP kinase pathway. 54 61
18989526 2008
21
Prostacyclin receptor-induced STAT3 phosphorylation in human erythroleukemia cells is mediated via Galpha(s) and Galpha(16) hybrid signaling. 54 61
18755267 2008
22
[Effects of some traditional Chinese drugs on Mdr1 gene and its expression product in K562/A02 cells]. 54 61
18718061 2008
23
The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells. 54 61
18424770 2008
24
EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. 61 54
18523154 2008
25
HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. 54 61
18059484 2008
26
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. 61 54
18094719 2008
27
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. 61 54
18245540 2008
28
PU.1: a crucial and versatile player in hematopoiesis and leukemia. 61 54
17374502 2008
29
Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells. 61 54
17713555 2007
30
Changes in the expression of cytochrome P450 genes in hemin-induced differentiated K562 cells. 61 54
17917270 2007
31
Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. 61 54
17852455 2007
32
Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. 54 61
17586475 2007
33
Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. 61 54
17646662 2007
34
Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. 61 54
17579122 2007
35
SATB1 regulates SPARC expression in K562 cell line through binding to a specific sequence in the third intron. 61 54
17343824 2007
36
Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. 61 54
17350650 2007
37
Heat shock factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1. 61 54
17213196 2007
38
Cyclic nucleotide response element binding (CREB) protein activation is involved in K562 erythroleukemia cells differentiation. 61 54
17063485 2007
39
Early growth response transcription factor EGR-1 regulates Galphaq gene in megakaryocytic cells. 61 54
16995904 2006
40
Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. 61 54
17022104 2006
41
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. 54 61
16598306 2006
42
Cyclic nucleotide Response Element Binding protein (CREB) activation promotes survival signal in human K562 erythroleukemia cells exposed to ionising radiation/etoposide combined treatment. 54 61
16819137 2006
43
Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. 54 61
16609039 2006
44
Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. 54 61
16332970 2006
45
Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. 54 61
16499875 2006
46
Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK. 61 54
15979846 2006
47
Regulation of globin gene transcription by heme in erythroleukemia cells: analysis of putative heme regulatory motifs in the p45 NF-E2 transcription factor. 61 54
16487039 2006
48
Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin. 54 61
16288996 2005
49
Cancer patient survival and erythropoietin. 61 54
16316615 2005
50
{gamma}-Globin gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established from human {beta}-globin locus yeast artificial chromosome ({beta}-YAC) transgenic mice. 61 54
16131492 2005

Variations for Acute Erythroid Leukemia

ClinVar genetic disease variations for Acute Erythroid Leukemia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ERBB3 NM_001982.3(ERBB3):c.4009G>A (p.Ala1337Thr) SNV Likely pathogenic 253223 rs755855285 GRCh37: 12:56495819-56495819
GRCh38: 12:56102035-56102035

Expression for Acute Erythroid Leukemia

Search GEO for disease gene expression data for Acute Erythroid Leukemia.

Pathways for Acute Erythroid Leukemia

GO Terms for Acute Erythroid Leukemia

Cellular components related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 9.63 SPI1 NFE2 KLF1 HSF2 GATA1 FLI1
2 host cell nucleus GO:0042025 9.43 NFE2 HSF2 FLI1
3 hemoglobin complex GO:0005833 8.96 HBG1 HBB
4 haptoglobin-hemoglobin complex GO:0031838 8.62 HBG1 HBB

Biological processes related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.95 SPI1 NFE2 KLF1 HSF2 GATA1 FLI1
2 regulation of transcription, DNA-templated GO:0006355 9.93 SPI1 NFE2 KLF1 HSF2 GATA1 FLI1
3 positive regulation of transcription, DNA-templated GO:0045893 9.8 SPI1 NFE2 KLF1 GATA1 FLI1 EPO
4 blood circulation GO:0008015 9.51 FLI1 EPO
5 hydrogen peroxide catabolic process GO:0042744 9.49 HBG1 HBB
6 interleukin-6-mediated signaling pathway GO:0070102 9.48 SPI1 JAK2
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.46 JAK2 ERBB3 EPOR EPO
8 oxygen transport GO:0015671 9.43 HBG1 HBB
9 positive regulation of Ras protein signal transduction GO:0046579 9.43 JAK2 EPOR EPO
10 erythropoietin-mediated signaling pathway GO:0038162 9.37 EPOR EPO
11 blood coagulation GO:0007596 9.35 NFE2 JAK2 HBG1 HBB GATA1
12 erythrocyte differentiation GO:0030218 9.02 SPI1 KLF1 JAK2 GATA1 EPO

Molecular functions related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.91 SPI1 NFE2 KLF1 HSF2 GATA1 FLI1
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.85 SPI1 NFE2 KLF1 HSF2 GATA1 FLI1
3 sequence-specific double-stranded DNA binding GO:1990837 9.81 NFE2 HSF2 GATA1 FLI1
4 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.8 SPI1 HSF2 GATA1 FLI1
5 heme binding GO:0020037 9.65 JAK2 HBG1 HBB
6 peroxidase activity GO:0004601 9.54 HBG1 HBB
7 oxygen binding GO:0019825 9.52 HBG1 HBB
8 oxygen carrier activity GO:0005344 9.46 HBG1 HBB
9 proximal promoter sequence-specific DNA binding GO:0000987 9.43 NFE2 KLF1 GATA1
10 organic acid binding GO:0043177 9.4 HBG1 HBB
11 sequence-specific DNA binding GO:0043565 9.35 SPI1 NFE2 HSF2 GATA1 FLI1
12 haptoglobin binding GO:0031720 9.32 HBG1 HBB
13 hemoglobin alpha binding GO:0031721 9.16 HBG1 HBB
14 DNA-binding transcription factor activity GO:0003700 9.1 SPI1 NFE2 KLF1 HSF2 GATA1 FLI1

Sources for Acute Erythroid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....